<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04482543</url>
  </required_header>
  <id_info>
    <org_study_id>23454</org_study_id>
    <nct_id>NCT04482543</nct_id>
  </id_info>
  <brief_title>Repeated Methotrexate for Proliferative Vitreoretinopathy Grade C</brief_title>
  <official_title>Repeated Intra-silicone Oil Injection of Methotrexate for Management of Proliferative Vitreoretinopathy Grade C; A Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter randomized clinical trial evaluates the effect of multiple intra-silicone
      oil injections of methotrexate (MTX) on rhegmatogenous retinal detachment (RRD) with grade C
      proliferative vitreoretinopathy (PVR).

      74 eyes with the diagnosis of RRD with PVR grade C will be randomized into two groups: the
      intervention group and the control group. All eyes undergo pars plana vitrectomy(PPV) and
      intraocular injection of silicone oil (SO). At the end of the surgical procedure, intra-SO
      injection of 250 µg MTX will be performed in the intervention group. No intra-SO injection
      will be done in the control group. In the intervention group, Intra-SO injection of MTX will
      be repeated at 3 and 6 weeks postoperatively. Silicone oil removal will be done 3 months
      after surgery.Spectral-domain optical coherence tomography (SD-OCT) image of the macula will
      be acquired at months 3 and 6. The retinal reattachment rate at months 6 will be assessed as
      the main outcome measure of the study. Best corrected visual acuity, retinal reproliferation
      rate and adverse events are the secondary outcome measures. Comprehensive ocular examination
      will be performed at weeks 1, 3, 6 and at months 3, 4 and 6.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal reattachment rate</measure>
    <time_frame>6 months</time_frame>
    <description>Funduscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Snellen chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal reproliferation rate</measure>
    <time_frame>6 months</time_frame>
    <description>Funduscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Slit-lamp, tonometry and funduscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Proliferative Vitreoretinopathy</condition>
  <arm_group>
    <arm_group_label>Intra-silicone oil injection of 250 µg methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No intra-silicone oil injection of methotrexate</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.</description>
    <arm_group_label>Intra-silicone oil injection of 250 µg methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rhegmatogenous retinal detachment with proliferative vitreoretinopathy grade C

        Exclusion Criteria:

          -  Age of under 18 years old

          -  Pregnancy

          -  Glaucoma

          -  Macular disorders

          -  Diabetic retinopathy

          -  Retinal vascular occlusion

          -  History of penetrating ocular trauma

          -  Giant retinal tear

          -  Chronic uveitis

          -  History of intraocular steroid injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hamid Ahmadieh, MD</last_name>
    <phone>+98 9122195871</phone>
    <email>hahmadieh@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamid Ahmadieh, MD</last_name>
      <phone>+98 9122195871</phone>
      <email>hahmadieh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 18, 2020</study_first_submitted>
  <study_first_submitted_qc>July 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 18, 2020</last_update_submitted>
  <last_update_submitted_qc>July 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Head of ophthalmic research center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

